Future therapeutic strategies targeting this multi-pathway regulatory network—such as combined targeting of YAP/TAZ with NF-κB, Wnt, or ER signaling—hold promise for improving treatment outcomes in head and neck cancer patients (Jiao et al., 2017; Wu and Yang, 2018; Yu et al., 2019). This evidence concerns the gene NFKB1 and head and neck cancer.